Literature DB >> 9124850

Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae.

C Sauve1, E Azoulay-Dupuis, P Moine, C Darras-Joly, V Rieux, C Carbon, J P Bédos.   

Abstract

We previously demonstrated the efficacy of ceftriaxone (CRO), at 50 mg/kg of body weight every 12 h, against a highly penicillin-resistant (MIC, 4 micrograms/ml) Streptococcus pneumoniae strain with low-level resistance to CRO (MIC, 0.5 microgram/ml) in a leukopenic-mouse pneumonia model (P. Moine, E. Vallée, E. Azoulay-Dupuis, P. Bourget, J.-P. Bédos, J. Bauchet, and J.-J. Pocidalo, Antimicrob. Agents Chemother. 38:1953-1958, 1994). In the present study, we assessed the activity of CRO versus those of cefotaxime (CTX) and amoxicillin (AMO) against two highly penicillin- and cephalosporin-resistant S. pneumoniae strains (P40422 and P40984) (MICs of 2 and 8 for penicillin, 2 and 4 for AMO, and 4 and 8 for CRO or CTX, respectively). Against both strains, a greater than an 80% cumulative survival rate was observed with CRO at a dose of 100 or 200 mg/kg every 12 h (dose/MIC ratio, 25). With CTX, a high dosage of 400 mg/kg (dose/MIC ratio, 100 or 50) administered every 8 h (TID) was needed to protect 66 and 75% of the animals, respectively, with no statistically significant differences versus CRO. Against the P40422 strain, CRO (100 mg/kg) produced the greatest bactericidal effect, from the 8th to the 24th hour after a single injection (1.8-log-unit reduction over 24 h), and the fastest bacterial pulmonary clearance during treatment; with CTX, only multiple injections at a high dosage, i.e., 400 mg/kg TID, demonstrated a significant bactericidal effect. AMO in a high dosage, 400 mg/kg (dose/MIC ratio, 200) TID, showed good activity only against the P40422 strain. Despite the identical MICs of CTX and CRO, the longer time (3.6 to 4.6 h) that serum CRO concentrations remained above the MICs for the pathogens at a dose of 100 mg/kg resulted in greater efficacy versus CTX against highly penicillin- and cephalosporin-resistant S. pneumoniae strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124850      PMCID: PMC163631     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Ro 13-9904: affinity for penicillin binding proteins and effect on cell wall synthesis.

Authors:  R B Wright; S D Makover; E Telep
Journal:  J Antibiot (Tokyo)       Date:  1981-05       Impact factor: 2.649

3.  Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumoniae to benzylpenicillin.

Authors:  R Williamson; A Tomasz
Journal:  Eur J Biochem       Date:  1985-09-16

4.  Penicillin-binding proteins of multiply antibiotic-resistant South African strains of Streptococcus pneumoniae.

Authors:  S Zighelboim; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

5.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

6.  Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins.

Authors:  N Frimodt-Møller; M W Bentzon; V F Thomsen
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

Review 7.  Pharmacokinetic profile of ceftriaxone in man.

Authors:  I H Patel; S A Kaplan
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

Review 8.  Antimicrobial activity of ceftriaxone: a review.

Authors:  R Cleeland; E Squires
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

9.  Community-acquired pneumonia requiring hospitalization: 5-year prospective study.

Authors:  T J Marrie; H Durant; L Yates
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

10.  In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.

Authors:  G Beskid; J G Christenson; R Cleeland; W DeLorenzo; P W Trown
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

View more
  14 in total

1.  Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin.

Authors:  Arnab Majhi; Rana Adhikary; Aritra Bhattacharyya; Sayantika Mahanti; Biswadev Bishayi
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Authors:  D P Nicolau; C O Onyeji; M Zhong; P R Tessier; M A Banevicius; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

4.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Authors:  Stephen W Barthold; Emir Hodzic; Denise M Imai; Sunlian Feng; Xiaohua Yang; Benjamin J Luft
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

6.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Generality of Post-Antimicrobial Treatment Persistence of Borrelia burgdorferi Strains N40 and B31 in Genetically Susceptible and Resistant Mouse Strains.

Authors:  Emir Hodzic; Denise M Imai; Edlin Escobar
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

8.  Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice.

Authors:  Jeffrey E Gotts; Lauren Chun; Jason Abbott; Xiaohui Fang; Naoki Takasaka; Stephen L Nishimura; Matthew L Springer; Suzaynn F Schick; Carolyn S Calfee; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

Review 9.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

10.  Could proteomic research deliver the next generation of treatments for pneumococcal meningitis?

Authors:  U R Goonetilleke; S A Ward; S B Gordon
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.